Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which molecular markers she seeks for NSCLC patients.

[powerpress]

Dr. Sarah Goldberg, from Yale Cancer Center, offers her view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified during first line chemotherapy. When should we switch treatments?

[powerpress]

Dr. Sarah Goldberg, from Yale Cancer Center, offers her insights on how to approach a patient with gradual progression in a single site, especially in the brain, or more multifocal progression after a good initial response to a targeted agent.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes the methods she uses to obtain tissue samples for molecular testing.

[powerpress]

Dr. Sarah Goldberg, Yale Cancer Center, reviews her thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.

[powerpress]

Dr. Sarah Goldberg addresses the question of whether to obtain molecular marker results in patients with early stage lung cancer and what to do with that information if it is available for potential application in the adjuvant setting.

[powerpress]

Dr. Sarah Goldberg notes that while maintenance therapy after first line treatment of advanced NSCLC is always worthy of a discussion, many patients need and benefit from a break from treatment to recover before pursuing additional therapy.

[powerpress]

Dr. Sarah Goldberg reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]